This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing Karyopharm's Subgroup Analysis SIENDO Study in Patients with TP53 Wild Type Endometrial Cancer for Selinexor as Maintenance Therapy

Ticker(s): KPTI

Who's the expert?

Institution: University of Leuven

  • Emeritus Professor with Scientific assignment at the Catholic University of Leuven and consultant at the University Hospitals Leuven
  • Main areas of clinical and translational research focus on gynecological cancer. He has authored more than 1020 original full papers in peer-reviewed journals. 
  • Currently Editor of the European Journal of Cancer

 

Interview Questions
Q1.

How many endometrial cancer patients do you treat?

Added By: wilson_admin
Q2.

What is your impression of selinexor safety profile?

Added By: wilson_admin
Q3.

How confident are you in the results of the subgroup analysis?

Added By: wilson_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.